Skip to main content

Table 4 Regression outputs mapped from HIT-6 (N = 10,971)

From: Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials

Utility values mapped from
HIT-6
Linear mixed effects model with REMLFractional response model (logit)Fractional response model (probit)Beta regression
Coeff95% CIp valueCoeff95% CIp valueCoeff95% CIp valueCoeff95% CIp value
Erenumab 70 mg (vs placebo)0.007−0.0020.0160.1510.037−0.0130.8700.1480.022−0.0080.0520.1430.032−0.0580.1230.484
Erenumab 140 mg (vs placebo)0.0200.0090.030<  0.0010.1120.0530.171<  0.0010.0670.0320.1010.00020.2020.0760.3280.002
Baseline MMD0.0002−0.0010.0010.6180.0100.0040.0160.0010.0050.0020.0090.0030.0450.0340.057<  0.001
MMD−0.012−0.013− 0.012<  0.001−0.070−0.075−0.065<  0.001−0.042−0.045−0.039<  0.001−0.096−0.107−0.086<  0.001
Visit
 Week 40.0320.0280.037<  0.0010.1490.1250.174<  0.0010.0890.0740.104<  0.0010.1490.0860.211<  0.001
 Week 80.0400.0360.045<  0.0010.1950.1660.223<  0.0010.1160.0990.133<  0.0010.2440.1730.316<  0.001
 Week 120.0430.0380.048<  0.0010.2100.1800.240<  0.0010.1240.1070.142<  0.0010.2490.1780.321<  0.001
 Week 160.030.0460.059<  0.0010.3120.2660.357<  0.0010.1810.1550.208<  0.0010.5120.4020.621<  0.001
 Week 200.0500.0440.057<  0.0010.3060.2600.353<  0.0010.1780.1510.205<  0.0010.5290.4110.647<  0.001
 Week 240.0500.0440.056<  0.0010.3090.2610.356<  0.0010.1800.1520.207<  0.0010.4720.3690.574<  0.001
Age0.00070.00030.001<  0.0010.0040.0020.006<  0.0010.0020.0010.004<  0.0010.0060.0010.0100.010
Female−0.0230.034−0.012<  0.001−0.135−0.201−0.069<  0.001−0.080−0.118−0.041<  0.001−0.128−0.252− 0.0040.042
Race (vs white)
 Black−0.014−0.0300.0030.101−0.061−0.1550.0330.203−0.036−0.0910.0190.1980.021−0.1490.1910.810
 Other−0.003−0.0280.2270.829−0.016−0.1780.1450.845−0.008−0.8650.0860.8650.244−0.1330.6220.205
RMSE0.1120.1130.1130.118
MAE0.0870.0880.0880.089
  1. Abbreviations: CI confidence interval, Coeff coefficient, HIT-6 Headache Impact Test, MAE mean absolute error, MMD monthly migraine day, MSQ Migraine-Specific Quality of Life Questionnaire, REML restricted maximum likelihood, RMSE root mean squared error